Orphan Drug Act Transforms Rare Disease Treatments in El Paso and Beyond

The Orphan Drug Act, enacted in 1983, has significantly changed the landscape of drug development for rare diseases, leading to over half of the FDA's new drug approvals in 2024 being for these conditions. This law incentivizes pharmaceutical companies to develop treatments for diseases affecting fewer than 200,000 people in the U.S., resulting in 26 out of 50 new drugs approved this year targeting rare diseases. Despite this progress, many rare diseases still lack approved treatments, affecting over 30 million Americans. The majority of orphan drug development is driven by smaller biotech firms, often founded by parents seeking cures for their children, highlighting a community-driven approach to addressing these medical needs.

Key Details: • In 2024, 26 out of 50 new FDA-approved drugs target rare diseases. • The Orphan Drug Act provides seven years of exclusive rights and tax credits for qualifying drugs. • Approximately 80% of identified rare diseases still lack FDA-approved treatments. • Rare diseases collectively affect over 30 million Americans, or about 1 in 10 people.